Quantum BioPharma announced that the FDA has placed a clinical hold on its Investigational New Drug application for Lucid-MS, a drug candidate for multiple sclerosis, requiring additional information before clinical trials can proceed. The company is reviewing the FDA's comments and plans to submit a response to address the issues raised. As a result, previous timelines for FDA review and trial milestones are withdrawn. Additionally, Dr. Lakshmi P. Kotra resigned from his director position but will remain as a senior clinical advisor. Quantum remains committed to advancing Lucid-MS responsibly and in compliance with regulatory requirements.
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ERock, Inc. received a buy rating due to its innovative modular natural-gas power systems that help data centers avoid long waits for permanent grid power. The company has a strong $1.3 billion backlog supported by customer deposits, providing clear ...
IBM's business model remains strong despite a 7% decline in mainframe infrastructure revenue, supported by loyal legacy customers and solid free cash flow. Software growth, especially an 11% increase in Red Hat revenue, helps offset mainframe challen...
BMW is recalling 29,119 plug-in hybrid sedans due to a potential fire risk caused by corrosion in the engine starter's electrical relay. This defect can lead to a short circuit and overheating even when the vehicle is parked with the ignition off. Th...
